Abstract
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease characterized by diffuse or segmental left ventricle (LV) hypertrophy associated with a nondilated ventricular chamber, in the absence of other cardiac or systemic disease that might be capable of producing the same degree of hypertrophy [1]. It is an important cause of sudden cardiac death in any age group. The prevalence of HCM is approximately 0.2–0.5 % of the general population.
Access provided by Autonomous University of Puebla. Download chapter PDF
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disease characterized by diffuse or segmental left ventricle (LV) hypertrophy associated with a nondilated ventricular chamber, in the absence of other cardiac or systemic disease that might be capable of producing the same degree of hypertrophy [1]. It is an important cause of sudden cardiac death in any age group. The prevalence of HCM is approximately 0.2–0.5 % of the general population.
Pathologic hallmarks of HCM are myocyte disarray and interstitial fibrosis [2]. HCM is inherited as an autosomal dominant trait and is caused by mutations in a sarcomeric gene which encodes protein components of the cardiac sarcomeres.
HCM can be seen as part of certain genetic and metabolic syndromes. These include Noonan syndrome (associated with pulmonary valve dysplasia and septal defects), mitochondrial myopathies, glycogen storage diseases (type II Pompe disease), as well as other rare conditions. In older patients, other systemic diseases associated with left ventricular hypertrophy (LVH) include hypertension, Friedrich ataxia, pheochromocytoma, neurofibromatosis, tuberous sclerosis, amyloidosis, lentiginosis (referring to the presence of lentigines or spotted areas on the skin due to sun exposure), and Fabry disease, a rare X-linked autosomal recessive metabolic storage disorder caused by a lack of lysosomal a-galactosidase [3].
Imaging plays a role in detecting HCM, characterizing its pattern (phenotype), classifying disease severity, and providing risk stratification criteria for sudden cardiac death. Echocardiography is the conventional imaging modality to screen for this condition, as it can characterize the pattern and distribution of increased LV wall thickness. However, it can underestimate the degree of LV hypertrophy, especially at the apical endocardial border.
Cardiac MRI using delayed gadolinium-enhancement technique provides information regarding the location and extent of fibrosis and is considered the examination of choice to establish the diagnosis of HCM when echocardiography is inconclusive. It allows multiplanar imaging which has the advantages of allowing complete coverage of the myocardium and better characterization of the pattern and distribution of LV hypertrophy.
Cardiac CT is not routinely used in patients with HCM since it is associated with radiation exposure. However, CT can be useful in those patients in whom detailed anatomy of the coronary arteries is needed and in patients with contraindications to MRI such as a pacemaker or aneurysm clips. The spatial resolution of CT is usually superior to MRI, allowing exquisite, noninvasive coronary artery angiography. Cardiac CT also provides comprehensive anatomical and functional information about the heart chambers and myocardium [4]. In retrospectively gated cardiac CT acquisition, systolic anterior motion (SAM) of the mitral valve can be easily assessed. In addition, delayed enhancement CT scanning provides information about myocardial scarring and fibrosis similar to that provided by MRI [5, 6]. CT has been reported to be useful in the assessment of patients undergoing septal alcohol ablation by enabling depiction of the exact extent and location of septal hypertrophy, systolic anterior motion of the mitral valve, and mitral valve leaflet–septal contact as well as septal perforator anatomy, which is of utmost importance in guiding septal ablation [7, 8]. See Table 10.1 for the utility of CT in the evaluation of HCM.
It should be noted that myocardial bridging is common in patients with apical hypertrophy and has been reported in the majority of patients presenting with typical or atypical chest pain [9]. It can lead to myocardial ischemia by narrowing the intramyocardial segment of the affected coronary artery, which can be especially well seen on CT.
1 Phenotype Analysis
HCM is diagnosed when the LV wall thickness (typically the septum) is ≥15 mm in the end-diastolic phase [10]. It can be classified based on the distribution of the wall hypertrophy into the following phenotypes: asymmetric (Fig. 10.1) with and without dynamic LV outflow tract (LVOT) obstruction, apical (Fig. 10.2), midventricular (Fig. 10.3), and symmetric, mass-like, and noncontiguous [9] (Figs. 10.4a and 10.5) (see Table 10.2). HCM does not involve the basal or inferolateral segments of the LV, a helpful feature in differentiating HCM from other causes of LV hypertrophy [11]. Occasionally apical infarct can be identified by CT in the absence of coronary artery disease as a result of constriction of a distal LAD bridge (Fig. 10.6, black arrow). Recently, left ventricular myocardial crypts have been identified as a distinctive morphologic expression of HCM, occurring in patients with and without hypertrophy. Crypts may identify individual HCM family members before development of typical phenotype. Crypts are confined to the basal LV, most commonly in the ventricular septum or posterior LV free wall [12]. Example of LV crypt is presented in Fig. 10.6 (white arrow).
2 Risk Stratification Criteria
Contrast-enhanced CT enables the diagnosis of HCM by enabling accurate measurements of the myocardial thickness and demonstration of the classic spade-shaped ventricular cavity during systole. In addition, it allows identification of risk stratification criteria associated with sudden cardiac death which include (a) LV maximal wall thickness 30 mm or more, (b) marked LV outflow tract obstruction (best assessed with echocardiography; CT can suggest the presence, but cannot confirm it or grade its severity), (c) decreased LV ejection fraction, (d) presence of fibrosis, and (e) presence of a perfusion defect indicating ischemia. Global LV functional volume analysis and ejection fraction are acquired using end-diastolic and end-systolic reformats of the CT data. Delayed myocardial enhancement can be used to characterize perfusion defects and fibrosis [11]. The presence of narrowing of the intramyocardial segment of a coronary artery, which can lead to myocardial ischemia, can also be identified on CT. In addition, CT can provide information on LV volume and the degree of mitral regurgitation [9].
3 Differential Diagnoses
The differential diagnoses of HCM include infiltrative diseases such as amyloidosis and sarcoidosis, which cause restrictive cardiomyopathy as well as LV hypertrophy due to aortic stenosis or hypertension.
In amyloidosis, amyloid protein is deposited in the myocardium, causing diffuse, symmetrical thickening of both ventricles and the septum and this thickening may involve the interatrial septum and atria.
Sarcoidosis, characterized by noncaseating granulomas, usually involves the interventricular septum (particularly the basal portion) and the lateral LV wall. Right ventricular infiltration with sarcoidosis is rare. In addition, cardiac sarcoidosis is an unusual finding in the absence of signs of other systemic involvement such as mediastinal lymphadenopathy or pulmonary parenchymal disease.
With aortic stenosis and systemic hypertension (compensatory LV hypertrophy), the LV wall undergoes compensatory hypertrophy caused by pressure overload and thus demonstrates a more concentric pattern of hypertrophy. Differentiation between HCM and compensatory hypertrophy can be difficult. In compensatory hypertrophy, systolic function is often normal and the LV wall rarely exceeds 15 mm in maximal thickness and rarely shows increased enhancement with contrast.
Occasionally, metastatic malignancy can present as focal hypertrophy (mimicking mass-like HCM) (Fig. 10.4b).
References
Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. Task Force on Clinical Expert Consensus Documents. American College of Cardiology, Committee for Practice Guidelines. European Society of Cardiology American college of Cardiology/European society of cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the american college of cardiology foundation task force on clinical expert consensus documents and the european society of cardiology committee for practice guidelines. J Am Coll Cardiol. 2003;42:1687–713.
Soor GS, Luk A, Ahn E, Abraham JR, Woo A, Ralph-Edwards A, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. 2009;62:226–35. doi:10.1136/jcp.2008.061655.
Chun EJ, Choi SI, Jin KN, Kwag HJ, Kim YJ, Choi BW, et al. Hypertrophic cardiomyopathy: assessment with MR imaging and multidetector CT. Radiographics. 2010;30:1309–28. doi:10.1148/rg.305095074.
Ghersin E, Lessick J, Litmanovich D, Engel A, Reisner S. Comprehensive multidetector CT assessment of apical hypertrophic cardiomyopathy. Br J Radiol. 2006;79:e200–4. doi:10.1259/bjr/53601277.
Saito H, Naito H, Takamiya M, Hamada S, Imakita S, Ohta M. Late enhancement of the left ventricular wall in hypertrophic cardiomyopathy by ultrafast computed tomography: a comparison with regional myocardial thickening. Br J Radiol. 1991;64:993–1000.
Shiozaki AA, Santos TS, Artega E, Rochitte CE. Images in cardiovascular medicine. myocardial delayed enhancement by computed tomography in hypertrophic cardiomyopathy. Circulation. 2007;115:e430–1.
Okayama S, Uemura S, Soeda T, Horii M, Saito Y. Role of cardiac computed tomography in planning and evaluating percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. J Cardiovasc Comput Tomogr. 2010;4:62–5. doi:10.1016/j.jcct.2009.10.004.
Ghersin E, Soto V, Heldman AW. Multidetector computerized tomography can guide and document alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2011;123:e5–7. doi:10.1161/CIRCULATIONAHA.110.975599.
Chen CC, Chen MT, Lei MH, Hsu YC, Chung SL, Sung YJ. Assessing myocardial bridging and left ventricular configuration by 64-slice computed tomography in patients with apical hypertrophic cardiomyopathy presenting with chest pain. J Comput Assist Tomogr. 2010;34:70–4.
Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002;287:1308–20.
Otto CM. Textbook of clinical echocardiography. Philadelphia: Saunders/Elsevier; 2009. p. 217–9.
Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(4):441–7. doi:10.1161/CIRCIMAGING.112.972760.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Mazur, W., Siegel, M.J., Miszalski-Jamka, T., Pelberg, R. (2013). Hypertrophic Cardiomyopathy. In: CT Atlas of Adult Congenital Heart Disease. Springer, London. https://doi.org/10.1007/978-1-4471-5088-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4471-5088-6_10
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-5087-9
Online ISBN: 978-1-4471-5088-6
eBook Packages: MedicineMedicine (R0)